Boosting a Drug's Market Share Can Cross a Dangerous Line
Reinke, T.
Managed Care 25(7): 36-39
2016
ISSN/ISBN: 1062-3388 PMID: 28121532 Document Number: 686035
Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.
Document emailed within 1 workday
Related Documents
Mertz, G. 2013: Boosting the bottom line of physician networks Healthcare Financial Management: Journal of the Healthcare Financial Management Association 67(6): 72-75Smith, R. 2000: UK is losing market share in pharmaceutical research Bmj 321(7268): 1041
Fey, R.A. 1986: Hospitals and physicians battle together for market share Health Care Strategic Management 4(10): 17-20
DiPaolo, V.; Johnson, D.E. 1979: Tax-exempt multihospital systems increase services, market share Modern Healthcare 9(10): 12-13
Lutz, S. 1990: Republic opts for ambulatory care to increase share of San Diego market Modern Healthcare 20(48): 37
Olson, G.; Talbert, P. 2012: Targeted population health management can help a hospital grow market share Healthcare Financial Management: Journal of the Healthcare Financial Management Association 66(6): 146-148; 150, 152
Gianfrate, F. 1999: Marketing lifestyle drugs==>to consumers = increased market share. 7-8 September 1999, London, UK IDrugs: the investigational drugs journal 2(11): 1143-1145
Szukaj, M. 1994: MDMA ("Ecstasy")--a dangerous drug or psychotherapeutic drug? Der Nervenarzt 65(11): 802-805
Piven', N.N.; Iliukhin, V.I.; Timoshin, V.B.; Viktorov, D.V.; Abramenko, A.V. 2005: Cross-reacting antigens of pathogenic Burkholderia and some dangerous causative agents of infectious diseases Zhurnal Mikrobiologii Epidemiologii i Immunobiologii 2005(2): 14-19
Taylor, M. 2002: Doc investors in for-profit hospitals denied staff privileges. Ohio not-for-profit systems fear loss of market share to specialty hospitals owned by physicians Modern Healthcare 32(28): 12-13
Masucci, J.J.A.; Caldwell, G.G.W.; Jones, W.W.J.; Juzwin, S.S.J.; Sasso, P.P.J.; Evangelisto, M. 2001: The use of on-line and off-line chromatographic extraction techniques coupled with mass spectrometry for support of in vivo and in vitro assays in drug discovery Current Topics in Medicinal Chemistry 1(5): 463-471
Wahlbeck, . 2018: To Share or not to Share Responsibility? Finnish Refugee Policy and the Hesitant Support for a Common European Asylum System Journal of Immigrant-Refugee Studies 17(3): 299-316
Santell, J.P.; Bruderle, T.P. 1993: Outpatient drug discounts for hospitals with a disproportionate share of indigent patients American Journal of Hospital Pharmacy 50(12): 2506-2508
Cohen, J. 1996: AIDS conference. Chemokines share center stage with drug therapies Science 273(5273): 302-303
Diamond, J.; Leeming, J. 1995: Chloramphenicol eye drops: a dangerous drug? Practitioner 239(1555): 608-611
Astrup, N. 1992: India: an expensive and dangerous drug Sygeplejersken 92(51): 36-38
De Benedetti, E.; Urban, P. 2007: Are drug-eluting stents dangerous? Revue Medicale Suisse 3(102): 656-658
Torsti, P. 1971: Is acetylsalicylic acid a dangerous drug? Duodecim; Laaketieteellinen Aikakauskirja 87(7): 492-494
Hensley, S. 1998: Out for blood. The newly overhauled American Red Cross is thirsty for a bigger share of the $2 billion business of supplying blood to hospitals Modern Healthcare 28(25): 26-8 30 32
Persson, S.A.; Eriksson, A.; Hallgren, N.; Eklund, A.; Berkowicz, A.; Druid, H. 2001: GHB--dangerous, addictive and uncontrollable "party drug" Lakartidningen 98(38): 4026